Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists

[Display omitted] A novel series of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as RORγt inverse agonists was discovered. Binding mode analysis of a RORγt partial agonist (2c) revealed by co-crystal structure in RORγt LBD suggests that the inverse agonists do not directly interfere with the interaction...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry Vol. 23; no. 17; pp. 5293 - 5302
Main Authors Wang, Yonghui, Yang, Ting, Liu, Qian, Ma, Yingli, Yang, Liuqing, Zhou, Ling, Xiang, Zhijun, Cheng, Ziqiang, Lu, Sijie, Orband-Miller, Lisa A., Zhang, Wei, Wu, Qianqian, Zhang, Kathleen, Li, Yi, Xiang, Jia-Ning, Elliott, John D., Leung, Stewart, Ren, Feng, Lin, Xichen
Format Journal Article
LanguageEnglish
Published OXFORD Elsevier Ltd 01.09.2015
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] A novel series of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as RORγt inverse agonists was discovered. Binding mode analysis of a RORγt partial agonist (2c) revealed by co-crystal structure in RORγt LBD suggests that the inverse agonists do not directly interfere with the interaction between H12 and the RORγt LBD. Detailed SAR exploration led to identification of potent RORγt inverse agonists such as 3m with a pIC50 of 8.0. Selected compounds in the series showed reasonable activity in Th17 cell differentiation assay as well as low intrinsic clearance in mouse liver microsomes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2015.07.068